RecruitingRecruiting
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336 · Eli Lilly and Company
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes
About this study
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them.
Participation in the study will last about 61 weeks.
Eligibility criteria
Inclusion Criteria:
* Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin
* Have HbA1c \> 6.5% to ≤ 11.0% at screening
* Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of \>85th percentile
Exclusion Criteria:
* Have type 1 diabetes
* After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome
* Have had at least one episode of severe hypoglycemia and/or at least one episode of hypoglycemic unawareness within the last 6 months before screening
* Have a history of pancreatitis or gallbladder disease
* Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
* Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or (SGLT2) inhibitors within 90 days prior to screening
* Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 90 days prior to screening
Study design
Enrollment target: 170 participants
Allocation: randomized
Masking: none
Age groups: child
Timeline
Starts: 2026-07-08
Estimated completion: 2030-03
Last updated: 2026-11-05
Interventions
Drug: OrforglipronDrug: Dulaglutide
Primary outcomes
- • Change from Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 40)
Sponsor
Eli Lilly and Company · industry
Contacts & investigators
ContactTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · contact · LillyTrials@Lilly.com · 317-615-4559
ContactPhysicians interested in becoming principal investigators please contact · contact · clinical_inquiry_hub@lilly.com
InvestigatorCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · study_director, Eli Lilly and Company
All locations (71)
Sutter Valley Medical Foundation (SVMF) Pediatric EndocrinologyRecruiting
Sacramento, California, United States
Rady Children's HospitalNot Yet Recruiting
San Diego, California, United States
Stamford Therapeutics ConsortiumRecruiting
Stamford, Connecticut, United States
Children's Healthcare of Atlanta - Center for Advanced Pediatrics (CAP)Not Yet Recruiting
Atlanta, Georgia, United States
CenExel iResearch, LLCRecruiting
Decatur, Georgia, United States
Medical Research PartnersRecruiting
Ammon, Idaho, United States
Cotton O'Neil Diabetes & EndocrinologyRecruiting
Topeka, Kansas, United States
SUNY Upstate Medical UniversityNot Yet Recruiting
Syracuse, New York, United States
Advantage Clinical TrialsRecruiting
The Bronx, New York, United States
Central States ResearchRecruiting
Tulsa, Oklahoma, United States
Frontier Clinical Research, LLCRecruiting
Smithfield, Pennsylvania, United States
Vanderbilt Health One Hundred OaksNot Yet Recruiting
Nashville, Tennessee, United States
Gadolin ResearchRecruiting
Beaumont, Texas, United States
Driscoll Children's HospitalRecruiting
Corpus Christi, Texas, United States
Proactive Clinical Research LLCRecruiting
Edinburg, Texas, United States
Consano Clinical Research, LLCRecruiting
Shavano Park, Texas, United States
Victoria Clinical Research GroupRecruiting
Victoria, Texas, United States
Cliniques universitaires Saint-LucNot Yet Recruiting
Brussels, Belgium
UZ GentNot Yet Recruiting
Ghent, Belgium
UZ LeuvenRecruiting
Leuven, Belgium
Instituto de Pesquisa clinica de CampinasNot Yet Recruiting
Campinas, Brazil
Centro de Pesquisa Sao LucasNot Yet Recruiting
Campinas, Brazil
Cendi - Endocrinologia e DiabetesNot Yet Recruiting
Goiânia, Brazil
Instituto Méderi de Pesquisa e SaúdeNot Yet Recruiting
Passo Fundo, Brazil
Instituto da Crianca com DiabetesNot Yet Recruiting
Porto Alegre, Brazil
Instituto de Pesquisa ClinicaNot Yet Recruiting
São Paulo, Brazil
IBTED - Tecnologia e Educação em DiabetesNot Yet Recruiting
São Paulo, Brazil
Avron HospitalsNot Yet Recruiting
Ahmedabad, India
Gujarat Endocrin Pvt LtdNot Yet Recruiting
Ahmedabad, India
Jawaharlal Nehru Medical CollegeNot Yet Recruiting
Aligarh, India
All India Institute of Medical SciencesNot Yet Recruiting
Bhubaneswar, India
Endolife Speciality HospitalsNot Yet Recruiting
Guntur, India
King Edward Memorial Hospital & Seth Gordhandas Sunderdas Medical CollegeNot Yet Recruiting
Mumbai, India
Harmony Health HubNot Yet Recruiting
Nashik, India
All India Institute of Medical SciencesNot Yet Recruiting
New Delhi, India
Ospedale Pediatrico SalesiNot Yet Recruiting
Ancona, Italy
Azienda Ospedaliera Universitaria Meyer IRCCSRecruiting
Florence, Italy
IRCCS Istituto Giannina GasliniNot Yet Recruiting
Genova, Italy
Azienda Ospedaliera Universitaria Di Messina G. MartinoNot Yet Recruiting
Messina, Italy
Ospedale San RaffaeleNot Yet Recruiting
Milan, Italy
University of Naples Federico IINot Yet Recruiting
Naples, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo TrentoNot Yet Recruiting
Verona, Italy
Nihon University HospitalRecruiting
Chiyoda-ku, Japan
Fukuoka Children's HospitalRecruiting
Fukuoka, Japan
Saitama Medical University HospitalRecruiting
Iruma, Japan
Shiga General HospitalRecruiting
Moriyama, Japan
Niigata University Medical & Dental HospitalRecruiting
Niigata, Japan
Osaka City General HospitalRecruiting
Osaka, Japan
Saitama City HospitalRecruiting
Saitama, Japan
Sendai City Hospital - AsutonagamachiRecruiting
Sendai, Japan
Shizuoka Children's HospitalRecruiting
Shizuoka, Japan
Urakami Pediatric Endocrinology and Diabetes ClinicRecruiting
Tokyo, Japan
Juntendo University Urayasu HospitalRecruiting
Urayasu, Japan
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C.Not Yet Recruiting
Ciudad Madero, Mexico
Centro de Investigacion Medica de Occidente, S.C.Not Yet Recruiting
Guadalajara, Mexico
UBAM Unidad Biomedica Avanzada MonterreyNot Yet Recruiting
Monterrey, Mexico
Clínica García Flores SCNot Yet Recruiting
Monterrey, Mexico
Centro de investigación y control metabólicoNot Yet Recruiting
Monterrey, Mexico
Soon Chun Hyang University Bucheon HospitalNot Yet Recruiting
Bucheon-si, South Korea
Kyungpook National University Chilgok HospitalNot Yet Recruiting
Deagu, South Korea
Chungnam national university hospitalNot Yet Recruiting
Junggu, South Korea
Seoul National University Bundang HospitalNot Yet Recruiting
Seongnam, South Korea
Seoul National University HospitalNot Yet Recruiting
Seoul, South Korea
Hospital Universitari Vall d'HebronNot Yet Recruiting
Barcelona, Spain
H.R.U Málaga - Hospital GeneralRecruiting
Málaga, Spain
Hospital Universitario Virgen Del RocioRecruiting
Seville, Spain
China Medical University HospitalNot Yet Recruiting
Taichung, Taiwan
Chang Gung Medical Foundation-Linkou BranchNot Yet Recruiting
Taoyuan, Taiwan
Hull Royal InfirmaryRecruiting
Hull, United Kingdom
Alder Hey Children's HospitalRecruiting
Liverpool, United Kingdom
Royal London HospitalNot Yet Recruiting
London, United Kingdom